(Reuters) - U.S. health regulators issued a warning letter to Bioniche Life Sciences Inc for publishing "false or misleading" information on Sotradecol, its drug to treat varicose veins. Certain web pages of Bioniche and distributor AngioDynamics Inc present efficacy claims for Sotradecol but fail to communicate any information about the risks associated with the product, the U.S. Food and ...

Stockhouse Canadian Small and Micro-cap Stock Report for Friday, July 10, 2009 TORONTO (SHfn) – Anglo Swiss Resources (TSX: V.ASW, Stock Forum) climbed as much as 20% to 39.5 cents on Friday after the micro cap miner said it assayed 2,696 ...

Shares of Bioniche Life Sciences (TSX: T.BNC, Stock Forum) jumped more than 28% to 59 cents Friday, as the Ontario-based biopharmaceutical firm announced that Endo Pharmaceuticals Inc. (NASDAQ: ENDP, Stock Forum) has licensed from Bioniche the exclusive rights to develop and market Urocidin in the U.S. with an option for global ...

Ontario-based Bioniche Life Sciences (TSX: T.BNC, Stock Forum) reported its financial results for the third quarter of its 2009 fiscal year Wednesday, including revenue of $7.4 million. For the third quarter, the company says consolidated revenues of $7.4 million compared to $7.2 million for the same quarter in fiscal 2008. Bioniche ...